Table 4 Subgroups analysis in the phenytoin vs. the New ASM groups
Adjusted HR (95 % CI)* | P for interaction | |
|---|---|---|
Sex | 0.41 | |
Male | 1.98(1.05–3.74) | |
Female | 1.35(0.73–2.49) | |
Index stroke type | 0.41 | |
Ischemic stroke | 1.52(0.95–2.45) | |
Hemorrhagic stroke | 2.42(0.74–7.97) | |
Hyperlipidemia | 0.04 | |
Yes | 2.76(1.37–5.56) | |
No | 1.11(0.63–1.96) | |
Ischemic heart disease | 0.79 | |
Yes | 1.59(0.90–2.82) | |
No | 1.84(0.92–3.70) | |
Heart failure | 0.83 | |
Yes | 2.04(0.73–5.68) | |
No | 1.70(1.03–2.78) | |
Atrial fibrillation | 0.75 | |
Yes | 1.35(0.60–3.06) | |
No | 1.69(1.00-2.86) | |
Mood disorder | 0.43 | |
Yes | 6.33(0.50–79.90) | |
No | 1.57(1.00-2.46) | |
Dementia | 0.18 | |
Yes | 1.15(0.52–2.53) | |
No | 1.95(1.14–3.33) | |
Migraine | 0.96 | |
Yes | - | |
No | 1.62(1.03–2.53) | |
Stroke severity index | 0.93 | |
Mild | 1.70(0.49–5.85) | |
Moderate | 1.86(1.05–3.30) | |
Severe | 1.15(0.48–2.77) | |
Concomitant anticoagulants use | 0.97 | |
Yes | - | |
No | 1.39(0.90–2.17) | |
Concomitant antidepressants use | 0.39 | |
Yes | 6.39(0.73–55.56) | |
No | 1.55(0.99–2.43) | |
Concomitant antiplatelet use | 0.55 | |
Yes | 1.54(0.85–2.77) | |
No | 1.66(0.85–3.24) | |
Concomitant Statin use | 0.09 | |
Yes | 8.07(0.98–66.76) | |
No | 1.38(0.88–2.17) | |
Medication use duration | 0.34 | |
< 90 days | 2.63(1.25–5.52) | |
90–179 days | 1.58(0.60–4.16) | |
≥ 180 days | 1.32(0.68–2.56) | |
Year of index date of ASM use | 0.96 | |
2001–2007 | 1.83(0.66–5.05) | |
2008–2013 | 1.92(1.18–3.13) |